Get started

JNJ

JNJ- short from today's open JNJ is very strong company but recently experiencing negative rollover with very sharp negative money-flow divergence. There are also insider selling as well. We like to short it from current level & our first target is 112.73 On the option side we are looking for Jan17- 120 put currently trading at $3.90 "You can check our detailed analysis on JNJ in the trading room/ Executive summery link here- www.youtube.com Time Span: 6:40" Trade Status: Pending
NYSE:JNJShort
by AcornWealthCorp
DSKX Major Acquisition(NASDAQ: DSKX) – Research Report Company Name: DS Healthcare Group Inc. Stock Symbol: DSKX Company Website: www.dslaboratories.com Trading at $1.53 Per Share (02/16/2016) Currently DSKX has a very attractive valuation with high analyst ratings, hedge fund interest, strengthened management team and major upcoming catalyst. DSKX is trading at a 33M market cap while they are expected to close on a major acquisition which is expected to increase the company’s annual revenues to approximately $65 million and $10 million in EBITDA with the combined businesses from over 20 countries, 900 unique and diversified products, and a broad range of personal care categories. This acquisition fiercely scales up and expands DS Healthcare’s business operations, product portfolio and distribution network in one deal. With the deal in place, DSKX is trading well below 1x expected annual sales while in the recent years many of its competitors in the industry sold at approximately 5x sales. Nioxin, Chattem, Simple Health & Beauty just to name a few. Several weeks ago, Frigate Ventures LP filed a SC 13G. In the filing, it appears Frigate Ventures LP owns 1,500,000 shares of DSKX. This shows Frigate Ventures Lp’s confidence and optimism in the future of the company and as a institutional investor with an excellent track record, its safe to assume they do their homework before buying a 7.1% stake in a company. Read the full research report using this link www.stockpicksnyc.com
DLong
by StockPicksNYC
Basic analysis shows JNJ is about to face strong resistanceA very basic analysis for $JNJ shows that the stock is facing a major resistance zone before earnings. The 98-100$ zone, a strong structure that held as support during more than a year, was broken during August and now became resistance. Add the 200 SMA line, the downtrend line and the sellers pressure that this stock will face when it will reach the psychological number of 100$ and you'll get pretty good reasons to be concern if you are still holding a bullish position in $JNJ.
NYSE:JNJ
by themarketzone
DOW JONES OVERVIEW: JNJ HOLDS LONG TERM TREND, SHORT TERM RISKJNJ micro picture currently contradicts macro one. On long term basis, JNJ has held the test of 10-year trend by falling below and then bouncing back up above the 10-year uptrend border (marked by 1st standard deviation from 10-year mean, now at 91) On short term basis, however, price has fallen below 1st standard deviations from quarterly (66-day) and 1-year (264-day) means, signaling continued downside probability. The downside risk remains until the price trades back up above short term risk border, marked by lower 1st standard deviation from 1-year mean (at 97 now)
NYSE:JNJ
by Killy_Mel
Johnson & Johnson vs USDJohnson & Johnson has seen extreme price consolidation since last November. Since they are a highly diversified healthcare company, currency translations affect their bottom line quite substantially. With the recent contraction of the US Dollar, Johnson & Johnson has broken out of a prolonged trading range. If the dollar continues to contract against other foreign currencies, Johnson & Johnson will make better on their hedges and increase the bottom line substantially, thus increasing free cash flow and overall economic opportunity.
NYSE:JNJLong
by dylpyckle